Newly Released Peer-Reviewed Publication Further Validates RepliCel’s Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.
Free to access editorial from our latest Regenerative Medicine issue by Gero Hütter
Free to access editorial from our latest Regenerative Medicine issue by Janelle Drouin-Ouellet and Roger A Barker
Human pluripotent stem cell (PSC) lines are valuable resources for regenerative medicine and drug discovery
Free editorial from our latest Regenerative Medicine issue by Carol Ware
Discussion of the public's attitude to stem cell treatment